Fulgent Genetics expanded its rare-disease testing lineup, adding 188 genes to its skeletal dysplasia panel and 29 to its vascular malformation panel. The company said the broader coverage is intended to improve diagnosis and is seeking clinician feedback.
published
Fulgent Genetics expanded its rare-disease testing lineup, adding 188 genes to its skeletal dysplasia panel and 29 to its vascular malformation panel. The company said the broader coverage is intended to improve diagnosis and is seeking clinician feedback.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.